SHIRE SP ADR (NASDAQ:SHPGY)
56.43
0.17 (0.3%)
| SHIRE SP ADR (NASDAQ:SHPGY) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $56.60 | 52 Week High | $60.32 | ||
| Open | $56.16 | 52 Week Low | $31.66 | ||
| Day High | $56.65 | P/E | N/A | ||
| Day Low | $55.88 | EPS | $0.00 | ||
| Volume | 308,580 | ||||
| More SHPGY Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| SHP | 18 | GENZ | 3 |
| GSK | 3 | CEPH | 2 |
| BAC | 1 | TXT | 1 |
| VRSK | 1 | HIG | 1 |
| KERX | 1 | ACOR | 1 |
| SCS | 1 | GPS | 1 |
Entities who have mentioned SHPGY
- UBS | View Related Stories »
- Lehman Brothers | View Related Stories »
- Citi | View Related Stories »
- Jefferies & Co | View Related Stories »
- Lazard | View Related Stories »
- Merrill Lynch | View Related Stories »
- Goldman Sachs | View Related Stories »
- JANA Partners LLC | View Related Stories »
- Barry Rosenstein | View Related Stories »
- Banc of America | View Related Stories »
- Dividend | View Related Stories »
- JPMorgan | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Credit Suisse | View Related Stories »
- Piper Jaffray | View Related Stories »
- Deutsche Bank | View Related Stories »
- Bear Stearns | View Related Stories »
- Robert W Baird | View Related Stories »
- Buckingham Research | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Collins Stewart | View Related Stories »
- Twitter | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- Raising Prices | View Related Stories »
- BMO Capital | View Related Stories »
View All ReportsStreetInsider.com Reports on SHPGY
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
- Caris & Co Downgrades Shire Ltd. (SHPGY) to Average
- Caris & Co. Downgrades Shire Ltd. (SHPGY) to Average
- Lazard Capital Downgrades Shire Ltd. (SHPGY) to Hold
- Shire Pharmaceuticals (SHPGY) calls active as shares rally
View All Press ReleasesCompany Press Releases on SHPGY
- Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
- Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
- Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
- Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
- Shire Extends Agreement with Medidata Solutions for Trial Planning Products
StreetInsider Reports on SHPGY by Category
View All BlogsBlogs on SHPGY
- Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold
- Analyst upgrades, downgrades and initiations: DLTR, JCP, JWN, LEA, RIMM, S ...
- Developments for Parkinson's Disease Ignite Investor Enthusiasm
- Shire plc Q3 2009 Earnings Call Transcript
- Genzyme: Focusing on Lumizyme Approval
View All FilingsSEC Filings on SHPGY
- Form 8-K Shire plc For: Nov 12
- Form 10-Q Shire plc For: Sep 30
- Form 8-K Shire plc For: Nov 02
- Form 8-K Shire plc For: Nov 04
- Form 8-K Shire plc For: Nov 02
Comments on recent SHPGY articles
Comments on SHPGY
No comments are currently available.
on Mar 18, 2008
at 09:51 AM Lifecell (LIFC) It was my understanding, that PFE was interested in Lifecell take over. Is this true?
Article: Shire plc (SHPGY) Higher On AstraZeneca Takeover Rumors